Dr Pascale Tomasini
- Spécialité
- Oncologue médical, expert poumon
- Hôpital
- AP-HM Hôpital Nord (Marseille)
- Derniers articles
-
- Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318. (11 août 2026)
- Dermatologic adverse events associated with amivantamab: A multicentre study. (1 août 2026)
- [Summary of second-line treatment of stage IV NSCLC without oncogenic addiction]. (1 mai 2026)
- Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center Cohort. (30 mars 2026)
- Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. (1 mars 2026)